Abstract 123: Revascularization Rate and Associated Costs Among Patients With Stable Ischemic Heart Disease Initiating Ranolazine versus Traditional Antianginals

Background: Real-world data are limited on resource utilization for revascularization procedures and associated healthcare costs for patients treated with ranolazine versus traditional antianginals. Objective: Describe frequency and costs of revascularization procedures among patients with stable ischemic heart disease (SIHD) initiating ranolazine versus traditional antianginals. Methods: Using Marketscan claims databases between 1/1/07-6/30/15, we identified adult patients with one of the following qualifying diagnosis codes: angina (stable or unstable), myocardial infarction, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) who initiated ranolazine or a traditional antianginal (beta-blocker [BB], calcium channel blocker [CCB], or long-acting nitrate [LAN]) as second or third line therapy. To be included, patients had to be continuously enrolled for ≥12 months prior to and after the date of qualifying antianginal prescription. Inverse probability weighting based on prope...